Biocon’s Q1 FY27 net profit rose to ₹141 crore from ₹31.4 crore a year ago, fueled by a 17% growth in the biopharma segment and lower finance costs. While biosimilars and generics performed well, the company’s services business reported a revenue decline. The stock ended 0.76% higher on the NSE following the results.
Biocon Ltd. reported a significant turnaround in its financial performance for the first quarter of the 2027 fiscal year. The pharmaceutical major posted a consolidated net profit of ₹141 crore, marking a nearly 349% increase compared to ₹31.4 crore in the same period last year. Consolidated revenue from operations for the quarter grew 10% year-on-year, reaching ₹4,336 crore.
Biopharma Segment Performance
The primary driver of this profit jump was the biopharma division, which saw revenue climb 17% to ₹3,615 crore. Within this division, the biosimilars segment grew by 16% to reach ₹2,855 crore, while the generics business recorded a 21% increase, totaling ₹760 crore. These segments have become central to the company’s revenue strategy, helping offset headwinds elsewhere in the business.
However, the company’s services segment faced pressure during the quarter, with revenue declining 16% to ₹736 crore. This divergence highlights a split in the company’s operational performance, where product-based businesses are scaling while the services vertical continues to navigate market challenges.
Finance Costs and Operational Efficiency
A critical factor supporting the bottom-line growth was the reduction in financial overheads. Finance costs for the quarter dropped by 23% to ₹213 crore, down from ₹277 crore in the previous year's quarter. This reduction is a result of the company’s efforts toward balance sheet optimization, which has helped lower the cost of borrowing. The company also reported an EBITDA of ₹902 crore, with margins holding at approximately 21%.
Recent Developments and Outlook
Biocon is actively expanding its product footprint in key markets. On August 3, 2026, the company launched Yesafili, a biosimilar to Aflibercept, in the United States. Additionally, it received Health Canada approval for its Yesintek autoinjector pen in late July 2026. Management has expressed optimism regarding the company's growth momentum, projecting a stronger performance in the second half of the fiscal year.
Investors looking ahead will focus on whether the company can maintain this growth in its biopharma segment while addressing the revenue decline in the services division. The stability of finance costs and the successful execution of new product launches in the U.S. and other regulated markets will remain key monitorables for the coming quarters.